Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-Current Debt (2018 - 2022)

Sutro Biopharma's Non-Current Debt history spans 5 years, with the latest figure at $3.8 million for Q4 2022.

  • For Q4 2022, Non-Current Debt fell 76.04% year-over-year to $3.8 million; the TTM value through Dec 2022 reached $3.8 million, down 76.04%, while the annual FY2022 figure was $3.8 million, 76.04% down from the prior year.
  • Non-Current Debt for Q4 2022 was $3.8 million at Sutro Biopharma, down from $6.8 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $24.7 million in Q1 2021 and bottomed at $3.8 million in Q4 2022.
  • The 5-year median for Non-Current Debt is $12.1 million (2018), against an average of $14.6 million.
  • The largest annual shift saw Non-Current Debt skyrocketed 343.84% in 2020 before it plummeted 76.04% in 2022.
  • A 5-year view of Non-Current Debt shows it stood at $10.0 million in 2018, then dropped by 11.24% to $8.9 million in 2019, then skyrocketed by 176.53% to $24.5 million in 2020, then plummeted by 35.88% to $15.7 million in 2021, then tumbled by 76.04% to $3.8 million in 2022.
  • Per Business Quant, the three most recent readings for STRO's Non-Current Debt are $3.8 million (Q4 2022), $6.8 million (Q3 2022), and $9.8 million (Q2 2022).